Skip to Content

As a result of the current Federal government funding situation, the information on this website may not be up to date or acted upon.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
Authors: Gayther SA,  Song H,  Ramus SJ,  Kjaer SK,  Whittemore AS,  Quaye L,  Tyrer J,  Shadforth D,  Hogdall E,  Hogdall C,  Blaeker J,  DiCioccio R,  McGuire V,  Webb PM,  Beesley J,  Green AC,  Whiteman DC,  Australian Ovarian Cancer Study Group,  Goodman MT,  Lurie G,  Carney ME,  Modugno F,  Ness RB,  Edwards RP,  Moysich KB,  Goode EL,  Couch FJ,  Cunningham JM,  Sellers TA,  Wu AH,  Pike MC,  Iversen ES,  Marks JR,  Garcia-Closas M,  Brinton L,  Lissowska J,  Peplonska B,  Easton DF,  Jacobs I,  Ponder BA,  Schildkraut J,  Pearce CL,  Chenevix-Trench G,  Berchuck A,  Pharoah PD,  Ovarian Cancer Association Consortium
Journal: Cancer Res
Date: 2007 Apr 1
Branches: MEB, OD, OEEB
PubMed ID: 17409409
PMC ID: not available
Abstract: High-risk susceptibility genes explain <40% of the excess risk of familial ovarian cancer. Therefore, other ovarian cancer susceptibility genes are likely to exist. We have used a single nucleotide polymorphism (SNP)-tagging approach to evaluate common variants in 13 genes involved in cell cycle control-CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, and CDKN2D-and risk of invasive epithelial ovarian cancer. We used a two-stage, multicenter, case-control study. In stage 1, 88 SNPs that tag common variation in these genes were genotyped in three studies from the United Kingdom, United States, and Denmark ( approximately 1,500 cases and 2,500 controls). Genotype frequencies in cases and controls were compared using logistic regression. In stage 2, eight other studies from Australia, Poland, and the United States ( approximately 2,000 cases and approximately 3,200 controls) were genotyped for the five most significant SNPs from stage 1. No SNP was significant in the stage 2 data alone. Using the combined stages 1 and 2 data set, CDKN2A rs3731257 and CDKN1B rs2066827 were associated with disease risk (unadjusted P trend = 0.008 and 0.036, respectively), but these were not significant after adjusting for multiple testing. Carrying the minor allele of these SNPs was found to be associated with reduced risk [OR, 0.91 (0.85-0.98) for rs3731257; and OR, 0.93 (0.87-0.995) for rs2066827]. In conclusion, we have found evidence that a single tagged SNP in both the CDKN2A and CDKN1B genes may be associated with reduced ovarian cancer risk. This study highlights the need for multicenter collaborations for genetic association studies.